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ABSTRACT
Objectives: Health-care policymakers and payers require cost-
effectiveness evidence to inform their treatment funding decisions. The
aims of this study were to assess the cost-effectiveness of the addition of
spinal cord stimulation (SCS) compared with conventional management
alone (CMM) in patients with complex regional pain syndrome (CRPS),
and to determine the cost-effectiveness of nonrechargeable versus
rechargeable SCS implanted pulse generators (IPGs).
Methods: A decision analytic model was used to synthesize data on
CRPS patient outcomes and health-care costs over a 15-year time
horizon from the perspective of the UK National Health Services. Data
were sourced from two SCS randomized controlled trials. Results are
expressed as an incremental cost per quality-adjusted life-year (QALY) in
2008 GBP.
Results: The incremental cost-effectiveness of SCS compared with CMM
was £3562 per QALY, a ﬁnding that was robust across sensitivity analyses
with an 87% probability that SCS is cost-effective at a willingness to pay
threshold of £30,000. When the longevity of an IPG is 4 years or less, a
rechargeable (and initially more expensive) IPG is more cost-effective than
a nonrechargeable IPG.
Conclusions: In selected patients with CRPS, SCS is cost-effective as an
adjunct to CMM. Despite their initial increased expense, rechargeable
IPGs should be considered when IPG longevity is likely to be short. These
ﬁndings support policymakers to extend the use of SCS as a good value for
money treatment for CRPS.
Keywords: complex regional pain syndrome, cost utility analysis, cost-
effectiveness, decision analytic modeling.
Introduction
The pathophysiology of complex regional pain syndrome type I
(CRPS I) is unknown, although the condition appears to be
associated with minor trauma. CRPS I is characterized by
ongoing pain, allodynia, functional impairment, abnormal
sweating, and abnormal vascular reactivity [1]. The syndrome is
associated with signiﬁcant morbidity, reduced functional ability,
and reduced health-related quality of life [2,3]. CRPS I has an
estimated incidence of 5.46 per 100,000 and prevalence 20.57
per 100,000 [2].
Various strategies have been used to reduce pain intensity in
CRPS, including conventional pain medication, physical therapy,
sympathetic blocks, and transcutaneous electrical nerve stimula-
tion, but largely with poor results [4].
Spinal cord stimulation has been used since 1967. Currently,
it is used to treat patients with intractable pain syndromes,
including CRPS [5]. The precise mechanism of pain modulation
is not fully understood. One theory is that it involves direct and
indirect inhibition of pain signal transmission, and to have auto-
nomic effects, the technique may inhibit chronic pain by stimu-
lating large diameter afferent nerve ﬁbers in the spinal cord. Pain
is masked by the production of numbness/tingling (paresthesia).
In a randomized controlled trial (RCT) that assessed SCS and
conventional medical management (CMM) versus CMM alone
in CRPS I, a signiﬁcant beneﬁt was demonstrated in patients
receiving SCS [6]. The results showed that at 6 months and
2-years follow-up, SCS reduced pain and improved health-
related quality of life [6,7]. Although the beneﬁts of SCS dimin-
ished with time, at 5-years follow-up, patients with a SCS
implant continued to show improved pain relief compared with
patients receiving CMM alone [8].
In addition to evidence for a clinical beneﬁt, health policy-
makers and payers increasingly request evidence of value for
money when making funding decisions [9,10]. In October 2008,
the United Kingdom’s (UK) National Institute of Health and
Clinical Excellence (NICE) analyzed the cost-effectiveness of SCS
and recommended that the UK National Health Service (NHS)
should offer the treatment to selected CRPS patients [11].
In this article, we update the NICE cost-effectiveness analysis
and also explore the cost-effectiveness of nonrechargeable versus
rechargeable SCS implanted pulse generators (IPGs).
Methods
We used an economic model to compare the cost-effectiveness of
the addition of SCS to CMM versus CMM alone. The analysis
was conducted from the perspective of the UK NHS.
Study Population
The model simulated a population of male and females patients
with CRPS I aged 18 to 65 years who fulﬁlled the diagnostic
criteria described by the International Association for the Study
of Pain [12], and as described by Kemler et al. [6]. The study
population had impaired function and symptoms beyond the
trauma, with the pain syndrome that affected one entire foot or
one entire hand for at least 6 months; patients had failed to
achieve a sustained response to conventional pain medication,
physical therapy, sympathetic blockade, or transcutaneous nerve
electrical stimulation, and had a pain intensity of at least 5 cm on
a visual-analogue scale (VAS) from 0 mm (no pain) to 100 mm
(very severe pain). Patients are excluded if they suffer from
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Raynaud’s disease, neurological abnormalities not related to
CRPS, other conditions affecting the function of the qualifying
extremity, a blood-clotting disorder or use of a pacemaker.
Model Structure
A two-stage decision analytic model was developed in Microsoft
EXCEL from a previously published model [13]. A decision tree
(Fig. 1) reﬂected possible initial 6-month responses to SCS [6],
and a Markov model simulated costs and quality-adjusted life-
years (QALYs) over a 15-year time horizon, which is within the
range of long-term observational SCS data [14].
In the decision tree, patients allocated to SCS ﬁrst underwent
a screening trial (patients eligible for SCS undergo a “screening
trial” where a percutaneous implantation is performed). In the
Kemler trial, 66.7% of screened patients achieved optimal pain
relief and therefore received a permanent implant, with the rest
receiving CMM (See Fig. 1) [6].
Figure 1 Two-stage model representations: (a) Six-month decision tree.Note: optimal pain relief is deﬁned as 50% reduction from baseline. (b) Long-term Markov
model. Note: Economic evaluations assume that the therapy being evaluated (e.g., SCS) is not available to patients in the CMM arm, hence, no patient in the
comparator arm can receive SCS in this model. Optimal pain relief is deﬁned as 50% reduction in perceived pain relief from baseline. SCS, spinal cord stimulation;
CMM, conservative medical management; Reop, reoperation; M, Markov model.
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Patients could experience one of six mutually exclusive health
states: optimal pain relief (at least 50% reduction in pain VAS
from baseline) with or without complications, suboptimal pain
relief (less than 50% reduction in pain VAS but more than zero)
with or without complications, no pain relief, or death.
During each subsequent 3-month Markov cycle, patients
allocated to SCS were assumed to remain in their health state
unless they: 1) experienced a complication; 2) moved from
optimal to sub-optimal pain relief; 3) moved to no pain relief
(and switched to CMM or reoperation); or 4) died. Cycle
length was chosen to represent a clinically meaningful time
interval.
Table 1a,b show the values assigned to each model probabil-
ity, utility, and cost.
Pain Relief and Complications
The primary clinical outcome in the model was the achievement
of at least a 50% reduction in pain VAS compared with baseline.
We used the 6-month results of the RCT of Kemler as the source
of data [6]. In addition to the published ﬁndings, we were able to
access the detailed patient level data from this trial. For patients
who continued to beneﬁt from SCS after six months, we esti-
mated the annual probability of losing pain relief (and switching
treatment) to be 3.24% [14].
Short-term SCS complication rates were sourced from the
Kemler trial, in which 25% of patients receiving an IPG experi-
enced a complication requiring intervention within the ﬁrst six
months [6]. The 5-year follow-up data for the Kemler trial was
used to calculate the long-term (6 months or more post-
implantation) SCS complications rate of 12.5% per annum.[8]
No complications related to CMM treatment were reported by
Kemler et al. [6–8].
Health-Related Quality of Life
Utility values for health states were based on responses to the
EuroQoL/EQ-5D questionnaire directly collected in the Kemler
trial at 6-months follow-up and using UK population weights
[15]. This yielded mean utility values of 0.195 for no pain relief,
0.581 for optimal pain relief. It was assumed that in patients with
optimal pain relief that a SCS complication had a negative impact
on utility, causing a disutility of -0.05 (Table 1b) [13].
Measuring and Valuing Health-Care Resource Use
Although costs of SCS and CMM were assessed in the Kemler
trial based on the level of health-care utilization, there are two
limitations with using these data in this analysis: 1) the assess-
ment of health-care utilization was limited to particular catego-
ries (e.g., drug medication was not recorded), and 2) ﬁxed unit
cost (“tariff”) for all patients were applied (e.g., the cost of SCS
screening was constant for all patients). Therefore, we sourced
costs from the PROCESS study, an international multicentre trial
that randomized failed back surgery syndrome (FBSS) patients to
receive either SCS and CMM or CMM [16]. The PROCESS
study undertook a detailed “bottom up” assessment of the level
of health utilization for each SCS and CMM patient [17]. Based
on a UK health-care perspective, we applied unit costs from
relevant sources and published estimates (Table 1b) (NHS
England, 2005–06; to each category of health-care utilization.
Results are reported in GBP sterling.
At 2008 prices provided by Medtronic, Inc., the cost of a
nonrechargeable IPG was £7761 (Synergy, Medtronic, Inc., Min-
neapolis, MN, USA), and a replacement unit was £7177. The
nonrechargeable IPG system cost £9762, and a replacement
system cost £9085 (see Table 1b). The rechargeable IPG system
(Restore Ultra, Medtronic, Inc.) cost £15,076, and a replacement
system cost £12,860. The Kemler trial reported that the IPG
would remain in situ for an average of approximately 4 years,
after which a replacement will be necessary [8].
At 2008 prices provided by Medtronic, Inc., a nonrecharge-
able IPG costs £7761 (Synergy), and its replacement costs £7177.
We compared a rechargeable IPG system (Restore Ultra, with a
cost of £15,076 and £12,860 for replacements and longevity of 9
years) with the nonrechargeable IPG system described earlier.
We discounted costs and QALYs at an annual rate of 3.5%
[18].
Cost-Effectiveness Reporting and Sensitivity Analyses
We conducted probabilistic sensitivity analysis (PSA) to account
for underlying parameter uncertainty (in a PSA, each parameter
is given a probability distribution, and uncertainty in all model
parameters is then explored simultaneously using 1000 Monte
Carlo simulation). The variables in the PSA included clinical
success, resource use, complication rate, and SCS failure rate
over time. We presented the results as cost-effectiveness accept-
ability curves [19], and judged them to be cost-effective on the
basis of maximum willingness to pay thresholds of £20,000 and
£30,000 per QALY [20].
To examine the impact of uncertainty on cost-effectiveness in
the model inputs, we performed one-way sensitivity analyses by
changing the base-case value of each model input parameter to its
upper and lower limits (see Table 1a,b) while holding all other
values constant. To identify the variables with greatest impact,
we plotted the results of the one-way sensitivity analyses in a
tornado diagram (See Fig. 2).
We separately examined the cost-effectiveness of use of a
rechargeable IPG (with an assumed longevity of 9 years com-
pared with a non-rechargeable IPG). This analysis is presented on
the net beneﬁt scale, that is, the maximum willingness to pay
threshold minus the incremental cost-effectiveness. A net beneﬁt
of zero or higher was considered to demonstrate cost-
effectiveness of a nonrechargeable SCS device compared with a
rechargeable device, and a negative net beneﬁt indicated the
opposite.
Results
Base-Case Analysis
Over the 15-year time period of the model, patients receiving SCS
accrued costs of £86,770 (Table 2). By comparison, a patient
receiving CMM alone accrued costs of £79,775, a difference of
£6994. This difference in cost is driven by the additional cost of
the SCS system (£9762) and any replacement IPGs necessary
(£7177 for a replacement unit).
Over the lifespan of the model, the SCS arm accrued an
additional 1.96 QALYs per patient compared with CMM alone,
resulting in an incremental cost-effectiveness ratio of £3562 per
QALY.
Sensitivity Analyses
One-way sensitivity analyses identiﬁed four variables that had
the greatest impact on the cost-effectiveness of SCS. The cost-
effectiveness of SCS increases as: 1) the cost of adjunct drug pain
therapy for SCS patients decreases; 2) time before a replacement
IPG is needed increases; 3) the cost of drug therapy in CMM
patients increases; and 4) the annual probability of no pain relief
with SCS decreases (Fig. 2). The fact that the incremental cost-
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effectiveness of SCS remained below the threshold of £20,000 per
QALY across all the ranges of one-way sensitivity analyses sup-
ports the robustness of the base-case analysis. There was also
evidence that SCS could be economically dominant (i.e., more
QALYs at lower costs) compared with CMM if the cost of
adjunct pain therapy for SCS patients is less than £1197 per
patient, the time before a replacement IPG is 7 years or more, or
the cost of drug therapy in CMM patients is higher than £4645
per patient.
Probabilistic sensitivity analysis (PSA) was also performed in
which each model parameter was varied around its mean using
appropriate distributions (see Table 1a,b). The results of the PSA
Table 1 (a) Summary model inputs—values and sources; (b) Summary of utilities and unit costs—values and sources
(a)
Model parameter Base-case value Source Sensitivity analysis range* Distribution Source
Probability of receiving SCS after
trial screening
SCS + CMM vs. CMM 0.667 Kemler et al. (2000) [6] 0.513–0.821 Beta 95% CI
SCS + CMM vs. CMM
Probability of successfully
screened patient achieving
optimal pain relief following
SCS + CMM
0.792 Kemler et al. (2000/2004/2008)
[6–8]
0.629–0.954 Beta 95% CI
Probability achieving optimal
pain relief following CMM
0.056 Kemler et al. (2000/2004/2008)
[6–8]
0.000–0.161 Beta 95% CI
Probability of complications
with CMM
0.000 Kemler et al. (2000) [6] 0.000–0.000 Beta 95% CI
Probability of patient receiving a
surgical revision achieving
optimal pain relief
0.188 Kemler et al. (2000/2004/2008)
[6–8]
0.000–0.379 Beta 95% CI
Probability of complication with
SCS requiring intervention in
ﬁrst 6 months
0.250 Kemler et al. (2000/2004/2008)
[6–8]
0.077–0.423 Beta 95% CI
Annual probability of
complication in ﬁrst year of
subsequent SCS implants
0.417 Kemler et al. (2000/2004/2008)
[6–8]
0.219–0.614 Beta 95% CI
Annual probability of
complication with SCS after 6
months
0.125 Kemler et al. (2000/2004/2008)
[6–8]
0.066–0.184 Beta 95% CI
Decrement in annual probability
of achieving optimal or
suboptimal pain relief with
SCS + CMM after 6 months
0.0324 Kumar et al. (2006) [14] 0.00–0.1577 Beta Min and max
Annual probability of death 0.0092 UK Ofﬁce National Statistics
[26]
0.0090–0.0094 Beta 10%
Longevity of IPG
(nonrechargeable)
4 years Kemler at al. 2000/2004/2008
[6–8]
2–10 Gamma Expert opinion
(b)
Parameter Base-case value Source Sensitivity analysis range† Distribution Source
Utility
Optimal pain 0.581 Kemler et al. (2000/2004/2008)
[6–8]
0.548–0.612 Beta Minimum and maximum
Suboptimal pain 0.195 Kemler et al. (2000/2004/2008)
[6–8]
0.212–0.329 Beta Minimum and maximum
SCS failure (no perceived pain
relief)
0.168 Kemler et al. (2000, 2004, 2008)
[6–8]
0.151–0.185 Beta Minimum and maximum
SCS complication -0.05 Taylor and Taylor (2005) [13] -0.10–0.00 Beta Expert opinion
SCS IPG costs
Screening for SCS £4069 Manca et al. (2008) [17] £2245–£6984 Gamma Minimum and maximum
Failed screening £1800 Manca et al. (2008) [17] £775–£3022 Gamma Minimum and maximum
SCS IPG implantation £9762 Manca [17] and Medtronic Inc‡ £9554–£14,900 Gamma Minimum and maximum
SCS IPG reimplantation £9085 Manca [17] and Medtronic Inc§ £7166–£11,890 Gamma Minimum and maximum
SCS IPG explantation £1800 Manca et al. (2008) [17] £0–£2536 Gamma Minimum and maximum
SCS IPG-related complication £622 Manca et al. (2008) [17] £203–£1572 Gamma Minimum and maximum
Drug treatment for pain cost
SCS + CMM £1692 Manca et al. (2008) [17]|| £0–£4493 Gamma Minimum and maximum
CMM £2664 Manca et al. (2008) [17]|| £0–£7075 Gamma Minimum and maximum
Non drug treatment for pain cost
SCS + CMM £28 Manca et al. (2008) [17]|| £0–£34 Gamma Minimum and maximum
CMM £804 Manca et al. (2008) [17]|| £0–£973 Gamma Minimum and maximum
*Range of parameter values used in probabilistic sensitivity analysis.
†Range of parameter values used in probabilistic sensitivity analysis.
‡System cost of £7761.
§IPG cost of £7177.
||Costs for 6-month period, subsequently annualized for the model.
CMM, conservative medical management; IPG, implanted pulse generator; QALY, quality-adjusted life-year; SCS, spinal cord stimulation.
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demonstrate that with a willingness to pay threshold of £20,000
per QALY, there is a 74% probability that SCS is cost-effective
increasing to an 87% probability when this threshold increases
to £30,000 per QALY (see Fig. 3).
Rechargeable Versus non-Rechargeable IPGs
In this analysis, it was assumed that the rechargeable IPG had a
ﬁxed battery life of 9 years, while nonrechargeable IPG longevity
was allowed to vary from 1 to 16 years. All other parameters
were the same for the two IPG systems. As shown in Figure 4,
rechargeable IPGs lasting 9 years are cost-effective at a threshold
of £20,000 per QALY, where the expected longevity of a non-
rechargeable IPG is less than 4 years (Fig. 4).
Discussion
Our model-based analysis shows that SCS is a cost-effective
addition to CMM in the treatment of CRPS I. The incremental
cost-effectiveness ratio for SCS relative to CMM alone falls
below the maximum willingness to pay threshold of £20,000 to
£30,000 per QALY used by policymakers in UK and many devel-
oped health-care economies [20].
This ﬁnding that SCS is cost-effective concurs with the one
previous economic evaluation of SCS in CRPS. Kemler and
Furnée in a trial-based analysis reported an incremental cost-
effectiveness ratio for SCS compared with CMM of €22,583 per
QALY (at 1998 prices) [21]. While still below the maximum
willingness threshold reported above, the higher incremental
cost-effectiveness ratio is reﬂective of the 1 year time horizon and
therefore the much-smaller QALY gain with SCS (+0.18 QALYs)
compared with that seen in the present study at 15 years (+1.96
QALYs). Modeling trial data over the remaining average of 41
years of life-expectancy of patients, Kemler and Furnée reported
SCS to be economically dominant, that is, lower costs and higher
QALYs compared with CMM. Given the absence of published
long-term follow-up data, we truncated our model extrapolation
at 15 years. Nevertheless, we were able to demonstrate in some
scenarios (longer IPG longevity and lower CMM costs) that SCS
was economically dominant compared with CMM.
Our incremental cost ratio for SCS relative to CMM was
lower than seen in the original assessment by NICE (£25,096 per
QALY) [22]. As part of the present analysis, we had access to the
individual patient data for the RCT of SCS for CRPS [6], and
therefore, we were able to direct estimate the proportion of
CMM-treated patients who achieved 50% of more pain relief
(i.e., 1 out of 18 patients, 5.6%). In the original NICE assess-
ment, this proportion was assumed to much higher (44%),
resulting in a smaller incremental QALY gain for SCS compared
with CMM (+0.35 QALYs) compared with the present analysis
(+1.96 QALYs). Given the incremental costs were similar (NICE
assessment: +£8775 vs. current analysis: +£8365), the incremen-
tal cost-effectiveness was lower in the present analysis.
As expected, we found that if the longevity of the nonre-
chargeable SCS IPG extends beyond the base-case assumption of
4 years, for the same IPG cost, the cost-effectiveness of SCS
becomes increasingly favorable. Conversely, if the stimulation
Figure 2 Incremental cost-effectiveness analysis—one-way sensitivity analyses.The intersections of the solid vertical lines with the x-axes represent incremental
cost-effectiveness per quality-adjusted life-year (ICER).The horizontal bars show the impact of varying the base-case value of various model parameters to their upper
and lower limits (see Tables 1 and 2) while holding all other values constant. A lower value than the base-case assumption demonstrates that SCS is more
cost-effective versus CMM.A higher value than the base-case assumption indicates that CMM is more cost-effective than SCS. SCS, spinal cord stimulation; CMM,
conservative medical management.
Table 2 Base-case incremental cost-effectiveness of SCS
SCS CMM Difference
Total cost/patient £86,770 £79,775 £6,994
QALYs/patient 4.84 2.88 1.96
Incremental cost per QALY £3,562
Note: Costs and QALYs discounted at 3.5% per annum, where £1.00 = US$ 1.62.
CMM, conservative medical management; QALY, quality-adjusted life-year; SCS, spinal cord
stimulation.
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requirements of a patient reduce the longevity of the IPG below
4 years, we found an initially more expensive rechargeable SCS
IPG becomes more cost-effective than a nonrechargeable IPG.
The model-based analysis by Hornberger showed that the use of
a rechargeable SCS IPG (assuming 10–25 years longevity) was
cost-saving compared with a nonrechargeable IPG over the
patient lifetime [23]. Nevertheless, in contrast to this cost-
consequence analysis, we have shown that the economic advan-
tage of rechargeable systems is limited to those CRPS patients
who are likely to have a short IPG longevity.
Strengths and Limitations
This study has several strengths. We used outcome and health-
care utilization data from RCTs [6,7] and a systematic review of
long-term observational follow-up of SCS [23]. We considered
long-term costs and outcomes, including the cost and clinical
impact of IPG-related complications and routine IPG replace-
ment. Long-term complications were sourced from the recent
long-term follow-up results of the Kemler RCT. We also compre-
hensively reﬂected uncertainty in model inputs. In contrast with
previous model-based analyses of SCS [13], our analysis uses
EQ-5D-based utility scores directly reported by CRPS patients
[21].
Our study also has potential limitations. First, given the lack of
detailed patient level health-care utilization data available from
the Kemler RCT, we instead sourced health-care costs from the
PROCESS trial [15]. Although the PROCESS trial was undertaken
in FBSS rather than CRPS patients, we believe that this source of
cost data has a number of strengths in the context of this study—it
is a large, multicenter RCT in SCS, and provides data from 12
centers inCanada, Europe, Australia, and Israel [14]; it is based on
a detailed assessment of the health-care utilization in individual
SCS and CMM patients over a 6-month follow-up period [15].
Also, current guidelines indicate that the breadth of drug and
nondrug therapy received by patients in the PROCESS is reﬂective
Figure 3 Cost-effectiveness acceptability curve. Illustrates the probability that SCS is cost-effective compared with CMM at differing maximal cost-effectiveness ratio
ceilings. SCS, spinal cord stimulation; CMM, conservative medical management.
Figure 4 The cost-effectiveness of a rechargeable (9-year lifespan) versus nonchargeable. IPG across differing nonrechargeable IPG lifetimes (assuming a maximum
willingness to pay of £20,000/QALY).A net beneﬁt of zero or higher demonstrates that the nonrechargeable IPG is cost-effective compared with the rechargeable
IPG, while a negative net beneﬁt indicates that the rechargeable IPG is more cost-effective than a nonrechargeable IPG. IPG, implanted pulse generator; QALY,
quality-adjusted life-year.
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of the pattern of care recommended for CRPS patients [5]. Second,
we did not have direct estimates of the disutility of complications
(associated with either SCS or CMM) from the Kemler RCT 6–8.
In accord with usual trial methodology, health-related quality of
life was assessed in this study at ﬁxed follow-up points rather than
at the time a complication occurred [13]. We applied both a cost
and disutility when a patient experienced a SCS-associated com-
plication. Nevertheless, for the purposes of modeling cost-
effectiveness, we made the conservative assumption of no
disutility or cost to be associated with these CMM-related events.
In the PROCESS trial, 4% of SCS patients and 23% of CMM
patients reported drug-related adverse events over a 12-month
period [16]. No CMM-related adverse events were reported in
Kemler trial 6–8. Finally, the time horizon of ourmodel is 15 years,
while the duration of the disease process is likely to be the patient’s
life expectancy. Given the lack of robust outcome data on SCS
cohorts beyond 15 years, however, we were reluctant to extrapo-
late costs and outcomes beyond this time.
Implications for Policy and Future Research
The cost-effectiveness ﬁndings of this study support the wide-
spread use of SCS for CRPS as an alternative to CMM alone and
underscore the 2008 NICE recommendation that SCS be offered
to adults with CRPS who experience chronic pain (measuring at
least 50 mm on a 0–100 VAS for at least 6 months) despite
appropriate CMM [11].
The potential population “need” for SCS in most countries is
uncertain [24]. Nonetheless, according to the Hospital Episode
Statistics, 32% of the estimated 639 patients who receive a SCS
implant in England in 2006 are patients with CRPS [25]. Assum-
ing a 5% annual growth, we project the cost of treating CRPS in
England to increase from £1.9 million to £2.3 million over a
5-year period.
In undertaking this analysis, we identiﬁed a number of areas
where further evidence collection would be particularly beneﬁ-
cial. First, given the rate of SCS success is inversely related to the
duration of chronic pain [14], a clinical trial and economic
evaluation are needed to examine the impact of moving SCS to a
position early in the treatment continuum for CRPS. Second, SCS
implant registries should be used to conﬁrm projected recharge-
able longevity estimates derived from battery decay algorithms
and to track patient outcomes. Finally, studies are needed to
assess the health-related quality of life impact of SCS-related
complications and drug-related adverse events.
Conclusions
In selected CRPS patients, SCS is a cost-effective option as an
adjunct to CMM with an incremental cost-effectiveness ratio
below the willingness to pay threshold of £20,000 to £30,000 per
QALY. When the longevity of an IPG is less than 4 years, a
rechargeable (and initially more expensive) IPG is the most cost-
effective option. These ﬁndings support the increased use of SCS
in the management of CRPS.
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